SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy.
SEngine Precision Medicine has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in July 2022.
SEngine Precision Medicine's investors include National Institutes of Health, Alethea Capital Management, Washington Research Foundation, Vincere Capital, Bangarang Group.
SEngine Precision Medicine is headquartered in Seattle, United States.
SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy.
SEngine Precision Medicine is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SEngine Precision Medicine — Funding & Investors." VCBacked, July 28, 2022, https://www.vcbacked.co/company/sengine-precision-medicine. Accessed September 2, 2026.
VCBacked. (2022). SEngine Precision Medicine — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/sengine-precision-medicine
{{cite web |title=SEngine Precision Medicine — Funding & Investors |url=https://www.vcbacked.co/company/sengine-precision-medicine |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated